ערך בספרים למניה: Galmed Pharma (GLMD)

Portfolio restructuring toward fibrosis treatment creates fierce competition for capital, which is evidenced by the volatility of the book value per share for Galmed Pharmaceuticals (GLMD). The latest value is recorded as 12.62. Brand stability is based on the safety of the Aramchol molecule and successes in treating orphan diseases. Market confidence is further bolstered by a unique platform for NAFLD therapy.

Galmed Pharmaceuticals' focus on developing combination therapies for liver diseases requires significant capital expenditures, which is reflected in the BVPS valuation via equity dynamics minus liabilities. Under US GAAP standards, this indicator measures the net asset value per share, allowing investors to compare the company's actual asset value against market risks and the effectiveness of management's scientific strategy.